罗格列酮对糖尿病大鼠血清高敏C反应蛋白和肾小球病理改变的影响

Effect of rosiglitazone on serum high sensitive C-reactive protein and glomerular pathological changes in diabetic rats

目的探讨糖尿病肾病大鼠肾小球病理改变和血清中高敏C反应蛋白(hs-CRP)的变化及罗格列酮干预后的影响。方法将40只SD大鼠随机分为正常对照组(C组)、糖尿病组(DM组)和罗格列酮干预组(DR组)。STZ诱导糖尿病大鼠模型,罗格列酮对DR组进行治疗性灌胃。10周后留取尿液测量尿微量白蛋白(MAU)、Glu、HbAlc、血脂采用ELISA法检测hs-CRP。在光镜、透射电镜下观察肾小球组织形态和超微结构的改变。结果DM组和DR组Glu、HbAlc、血脂差别无统计学意义(P>0.05)。DM组和DR组血清hs-CRP、MAU较C组明显增高,DR组低于DM组,差别有统计学意义(P<0.01)。血清hs-CRP与MAU呈显著正相关(r=0.725,P<0.01)。DR组肾小球病理改变较DM组明显改善。结论hs-CRP的水平与糖尿病肾病的严重程度一致,罗格列酮可以通过减低血清hs-CRP的水平,减轻炎症反应,起到保护肾脏的作用。

Objective To investigate the effect of rosiglitazone on serum high sensitive C-reactive protein（hs-CRP） and glomerular pathological changes in diabetic rats. Methods Forty SD rats were divided into normal control group（group C）, diabetes mellitus group（group DM） and rosiglitazone treated diabetes mellitus group（group DR）. Diabetes was induced by streptozocin（STZ）, and group DR received rosiglitazone through perfusing stomach. Glu, HbAlc, blood lipid protein and MAU were measured ten weeks later. Serum hs-CRP was detected by ELISA. Morphologic and ultrastructure changes of glomcrulus were observed. Results There were no statistic significance in Glu,HbAlc,blood lipid protein between groups DR and DM（P〉0.05）. Serum hs-CRP and MAU were significantly higher in group DM than those in group C and group DR（P〈0. 01）. The change of hs-CRP was positively correlated with MAU（r=0. 725 ,P〈0. 01）. In group DR pathological changes were improvded compared to those in group DM. Conclusion The concetration of serum hs-CRP is corresponded with the degree of diabetic nephropathy. Rosiglitazone can protect the kidneys of diabetic rats through decreasing serum C-reactive protein concetration and relieving inflammation reaction.